U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C5H6NO3.Mg
Molecular Weight 280.5171
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM PIDOLATE

SMILES

[Mg++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2

InChI

InChIKey=JQAACYUZYRBHGG-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Mg/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1

HIDE SMILES / InChI

Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H6NO3
Molecular Weight 128.106
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.

CNS Activity

Curator's Comment: Known to penetrate blood-brain barrier in rats. Is produced naturally in human brain

Originator

Sources: Haitinger, L.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel

Approved Use

Lange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne.

Launch Date

2012
Primary
Unknown

Approved Use

Unknown
Primary
EcoCare™ Zinclean

Approved Use

Use in anti-dandruff shampoos
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii.
2002
Characterizing degradation products of peptides containing N-terminal Cys residues by (off-line high-performance liquid chromatography)/matrix-assisted laser desorption/ionization quadrupole time-of-flight measurements.
2003
Determination of the post-translational modifications of salivary acidic proline-rich proteins.
2003 Apr
Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin.
2003 Apr
Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization.
2003 Aug 15
Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1.
2003 Aug 19
Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors.
2003 Aug 7
Pressure/temperature combined treatments of precursors yield hormone-like peptides with pyroglutamate at the N terminus.
2003 Dec 31
Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana.
2003 Feb 28
Isolation and identification of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale.
2003 Jan 1
[Neuroprotective properties of pyroglutamic acid in combination with pyrrolidone].
2003 Jan-Feb
Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus.
2003 Jul
Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues.
2003 Jul 7
2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation.
2003 Jun 7
Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator.
2003 Mar
[Evolution of the neuroprotection concept].
2003 Mar-Apr
[Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism].
2003 May
Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation.
2003 May
[Characteristics of pyrrolidone pharmacokinetics in rats].
2003 Nov-Dec
Structural characterization of native mouse zona pellucida proteins using mass spectrometry.
2003 Sep 5
Origin of diastereoselection in the hydrosilylation of chiral N-acyliminium intermediates derived from pyroglutamic acid.
2004 Apr 26
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.
2004 Apr 9
Glutamine in commercial liquid nutritional products.
2004 Aug 11
Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis.
2004 Feb
Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies.
2004 Feb
Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells.
2004 Feb
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site.
2004 Feb 10
Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry.
2004 Feb 24
N-acetylation of the glutamate residue of intact glutathione conjugates in rats: a novel pathway for the metabolic processing of thiol adducts of xenobiotics.
2004 Jan
Integrative annotation of 21,037 human genes validated by full-length cDNA clones.
2004 Jun
Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections.
2004 Mar
Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid.
2004 Mar
Synthesis of (2S,3S)-3'-fluoroisoleucine.
2004 Mar 7
Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures.
2004 Mar-Apr
Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein.
2004 May 25
Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline.
2004 May 7
Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.
2004 May-Jun
Discrepin, a new peptide of the sub-family alpha-ktx15, isolated from the scorpion Tityus discrepans irreversibly blocks K+ -channels (IA currents) of cerebellum granular cells.
2004 Oct 15
Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin.
2004 Oct 19
Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions.
2004 Sep
Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
2004 Sep
Mass spectrometry analysis of recombinant human ZP3 expressed in glycosylation-deficient CHO cells.
2004 Sep 28
Nanoparticles on the basis of highly functionalized dextrans.
2005 Aug 3
Physiological and pathological aspects of GSH metabolism.
2005 Feb
Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid).
2005 Jul
The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains.
2005 Jul 1
Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques.
2005 Nov 4
Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology.
2005 Sep 21
Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.).
2005 Sep 25
CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts.
2006 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Sources: Topical, as a compontent of lotions, creams and other cosmetic products.
Topical, as a compontent of lotions, creams and other cosmetic products.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:22 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:22 GMT 2025
Record UNII
V5PC588N7G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM PCA
INCI  
INCI  
Preferred Name English
MAGNESIUM PIDOLATE
EP   MART.   WHO-DD  
Common Name English
MAGNESIUM PIDOLATE [MART.]
Common Name English
Magnesium pidolate [WHO-DD]
Common Name English
PIDOLIC ACID MAGNESIUM SALT (2:1)
Common Name English
L-PROLINE, 5-OXO-, MAGNESIUM SALT (2:1)
Common Name English
MAGNESIUM PIDOLATE [EP MONOGRAPH]
Common Name English
MAGNESIUM PYROGLUTAMATE
Common Name English
Classification Tree Code System Code
WHO-VATC QA12CC08
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
WHO-ATC A12CC08
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
Code System Code Type Description
WIKIPEDIA
MAGNESIUM PIDOLATE
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
DRUG BANK
DBSALT002689
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL397976
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
FDA UNII
V5PC588N7G
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
DAILYMED
V5PC588N7G
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
PUBCHEM
14559042
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
SMS_ID
100000089075
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
RXCUI
116240
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
4597
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
ECHA (EC/EINECS)
263-365-7
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
EVMPD
SUB03045MIG
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
CAS
62003-27-4
Created by admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY